Cargando…

Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report

INTRODUCTION: Every eye with central retinal vein occlusion (CRVO) is at risk for developing neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Alasil, Tarek, Rauser, Michael E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783132/
https://www.ncbi.nlm.nih.gov/pubmed/19946487
http://dx.doi.org/10.1186/1757-1626-2-176
_version_ 1782174683505885184
author Alasil, Tarek
Rauser, Michael E
author_facet Alasil, Tarek
Rauser, Michael E
author_sort Alasil, Tarek
collection PubMed
description INTRODUCTION: Every eye with central retinal vein occlusion (CRVO) is at risk for developing neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant monoclonal antibody binding all isoforms of VEGF. Several studies have demonstrated intravitreal bevacizumab-induced regression of iris and angle neovascularisation associated with NVG. CASE PRESENTATION: A 74 year old female presented with acute onset decreased vision in the right eye. Ophthalmic exam revealed acute non-ischemic CRVO in the right eye. A month later, follow up exam showed progression into ischemic CRVO and secondary NVG, which was successfully treated with intravitreal Bevacizumab followed by pan retinal photocoagulation (PRP). CONCLUSION: Our case report highlights the use of intravitreal Bevacizumab in combination with PRP for the treatment of NVG secondary to CRVO.
format Text
id pubmed-2783132
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27831322009-11-28 Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report Alasil, Tarek Rauser, Michael E Cases J Case Report INTRODUCTION: Every eye with central retinal vein occlusion (CRVO) is at risk for developing neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant monoclonal antibody binding all isoforms of VEGF. Several studies have demonstrated intravitreal bevacizumab-induced regression of iris and angle neovascularisation associated with NVG. CASE PRESENTATION: A 74 year old female presented with acute onset decreased vision in the right eye. Ophthalmic exam revealed acute non-ischemic CRVO in the right eye. A month later, follow up exam showed progression into ischemic CRVO and secondary NVG, which was successfully treated with intravitreal Bevacizumab followed by pan retinal photocoagulation (PRP). CONCLUSION: Our case report highlights the use of intravitreal Bevacizumab in combination with PRP for the treatment of NVG secondary to CRVO. BioMed Central 2009-10-30 /pmc/articles/PMC2783132/ /pubmed/19946487 http://dx.doi.org/10.1186/1757-1626-2-176 Text en Copyright ©2009 Alasil and Rauser; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Alasil, Tarek
Rauser, Michael E
Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
title Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
title_full Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
title_fullStr Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
title_full_unstemmed Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
title_short Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
title_sort intravitreal bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783132/
https://www.ncbi.nlm.nih.gov/pubmed/19946487
http://dx.doi.org/10.1186/1757-1626-2-176
work_keys_str_mv AT alasiltarek intravitrealbevacizumabinthetreatmentofneovascularglaucomasecondarytocentralretinalveinocclusionacasereport
AT rausermichaele intravitrealbevacizumabinthetreatmentofneovascularglaucomasecondarytocentralretinalveinocclusionacasereport